Alejandro Gutierrez, M.D., assistant professor, pediatrics, Harvard Medical School; staff physician, hematology/oncology, Boston Children's Hospital; staff physician, pediatric oncology, Dana-Farber Cancer Institute
Yardira Soto-Feliciano, Ph.D., postdoctoral fellow, Damon Runyon-Sohn Pediatric Cancer Fellow; laboratory of chromatin biology and epigenetics , The Rockefeller University
Alejandro Gutierrez, M.D., assistant professor, pediatrics, Harvard Medical School; staff physician, hematology/oncology, Boston Children's Hospital; staff physician, pediatric oncology, Dana-Farber Cancer Institute
Yardira Soto-Feliciano, Ph.D., postdoctoral fellow, Damon Runyon-Sohn Pediatric Cancer Fellow; laboratory of chromatin biology and epigenetics, The Rockefeller University
Cheryl H. Arrowsmith, Ph.D., chief scientist, Structural Genomics Consortium; senior scientist, Ontario Cancer Institute / Princess Margaret Cancer Centre; professor, department of medical biophysics, University of Toronto
A rich program of lectures and seminars featuring internal and external speakers help Rockefeller scientists keep abreast of their colleagues’ work and forge fruitful interdisciplinary collaborations.
A study from the Nussenzweig lab shows that the immune system mounts lasting defense after recovery from COVID-19. The study participants continued to improve their antibodies months after initial infection, potentially due to exposure to the remnants of the virus hidden in the gut. #Rockefellerscience... See MoreSee Less
With green light from the FDA, Rockefeller scientists have started human trials this week for a new monoclonal antibody drug as a treatment for COVID-19. Patients in the clinical trial will receive two highly potent antibodies against SARS-CoV-2 discovered by Michel Nussenzweig and colleagues. Designed to prevent people with early COVID-19 from developing severe disease, the treatment is urgently needed as hospitals continue to be inundated by repeated surges of infection, and mass vaccinations are still months away. Thank you to Harrington Discovery Institute (University Hospitals) for generous support of Dr. Nussenzweig’s project. #RockefellerScience ... See MoreSee Less
These associations are raising the really exciting notion that perhaps the presence of brown fat protects against these obesity-associated diseases. —Paul Cohen in The Scientist... See MoreSee Less
A study from Sandy Simon's lab shows that the nuclear pore, often considered a passive portal between the cell and the nucleus, is in fact a flexible structure of dynamic proteins. Here the researchers recreate the pore's movements with lightsabers! #Rockefellersciencebit.ly/2Lj8Pa5... See MoreSee Less
A study from the @NussenzweigL shows that the immune system mounts lasting defense after recovery from #COVID19, potentially from exposure to the remnants of the virus hidden in the gut. #RockefellerScience
https://t.co/ke5Ku8Aldn
On Monday we launched into the first session of @RockefellerUniv Talking Science! This year's series is titled "The COVID-19 Pandemic: Insights and Overview".
Weren't able to make it? Check out the full clip with Dr. Marina Caskey!⬇️
On April 1, 2020 we started studying COVID-19 survivors. Today, only 287 days later, we administered two newly discovered antibodies to our first study volunteer. These can potentially prevent & treat COVID-19. Breathtaking science from bench to bedside 🙏 https://t.co/fn4UYilXOd
With green light from the FDA, Rockefeller scientists have started human trials for a new monoclonal antibody drug as a treatment for #COVID19. The therapy, developed by @NussenzweigL and others, has potential to prevent the disease from becoming severe.
https://t.co/Y318S3sWXA
These associations are raising the really exciting notion that perhaps the presence of brown fat protects against these obesity-associated diseases. —Paul Cohen, the Rockefeller University / @RockefellerUniv https://t.co/qiD6PbvzKo
